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Hypoxia-inducible factor-1 (HIF-1) is a key heterodimeric transcription factor for the cellular adaptive response to hypoxia, a 
common feature of the microenvironment in solid tumors. The transcriptional activity, protein stabilization, protein-protein in-
teractions and cellular localization of HIF-1, an oxygen-sensitive subunit of HIF-1, are mainly modulated by various 
post-translational modifications. Recently, we reported that polycomb chromobox 4 (Cbx4) governs the transcriptional activity 
of HIF-1α by enhancing its sumoylation at K391 and K477, through which Cbx4 potentiates angiogenesis of hepatocellular 
carcinoma. This review summarizes the current knowledge of HIF-1 sumoylation and its roles in the pathogenesis of cancer. 
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Hypoxia, a common characteristic of the microenvironment 
for cancer cells, promotes changes in metabolism (e.g., 
changes from oxidative phosphorylation to glycolysis), and 
the progression and metastasis of solid tumors [13]. Tran-
scription factors known as hypoxia-inducible factors (HIFs) 
bind hypoxia responsive elements (HREs) within the pro-
moter regions of their target genes [4,5]. HIF target genes 
include those involved in the regulation of hematopoietic 
and vascular development, cellular glucose uptake and me-
tabolism, cell proliferation and differentiation, pH homeo-
stasis, cell death and autophagy [6–14].  
HIF heterodimer comprises one of three major oxy-
gen-sensitive HIF- subunits (HIF-1, HIF-2 or HIF-3) 
and a constitutively expressed β-subunit (HIF-1β, also 
known as aryl hydrocarbon receptor nuclear translocator, 
ARNT). These subunits join together to form the HIF-1, 
HIF-2 and HIF-3 transcriptional complexes, respectively. 
The hypoxic response is primarily mediated by the hypox-
ia-inducible HIF-1 and HIF-2 complexes, which have both 
overlapping and unique target genes [5]. Their transcrip-
tional activities, protein stabilization, protein-protein inter-
actions, and cellular localization are mainly modulated by 
post-translational modifications such as hydroxylation, 
ubiquitination, acetylation, phosphorylation and S-nitrosyl- 
ation [15,16]. Recently, we reported that polycomb chro-
mobox 4 (Cbx4, Figure 1A) governs the transcriptional ac-
tivity of HIF-1α by enhancing its sumoylation, and hence 
potentiating angiogenesis of hepatocellular carcinoma 
(HCC) [17]. Here we review the current understanding of 
HIF-1 sumoylation, and its effects on protein stabilization 
and transcriptional activity of HIF-1, as well as its roles in 
the pathogenesis of cancer. 
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Figure 1  The schematic structure of Cbx4 (A) and HIF-1 proteins (B). 
1  Ubiquitin-dependent and independent deg-
radation of HIF-1 protein 
The human HIF-1 subunit contains 826 amino acids with 
an approximate molecular weight of 120 kD [18]. The 
schematic structure of HIF-1 protein is shown in Figure 
1B. It carries two nuclear localization sequences that are 
responsible for translocation of the accumulated HIF-1 
protein to the nucleus under hypoxic conditions [19]. The 
transcriptional activity of HIF-1 is determined by two 
transactivation domains (TADs) respectively in its 
N-terminal and C-terminal [2022]. Deletion of amino acids 
576–785 of HIF-1 increases its transcriptional activity [20], 
suggesting that this region possibly contains an inhibitory 
domain. HIF-1 also contains a basic helix-loop-helix 
(bHLH) domain that mediates its dimerization with HIF-1 
subunits, and a Per-Arnt-Sim domain (PAS) to be responsi-
ble for DNA binding [21]. Intriguingly, most post-transla- 
tional modifications occur within the oxygen-dependent 
degradation domain (ODDD) which plays a crucial role in 
the hypoxia-dependent stabilization of HIF-1 [23].  
Under normoxic conditions, prolyl hydroxylases 13 
(PHD13) hydroxylate the proline residues at positions 402 
and 564 within the ODDD of HIF-1 [24,25]. HIF-1 hydrox-
ylation is essential for the binding of the von Hippel-Lindau 
(VHL) tumor suppressor protein, one component of a mul-
tiple protein ubiquitin-ligase complex VHL/elongin B/ 
elongin C [26–28]. This E3 ubiquitin ligase complex   
links a ubiquitin chain to HIF-1α and directs it to the pro-
teasome complex for proteolytic degradation [29]. As PHDs 
use oxygen as a cofactor for their hydroxylation activity, 
these enzymes become inactive under hypoxic conditions, 
resulting in non-hydroxylation of prolines 402 and 564, and 
inhibition of VHL binding. Consequently, the HIF-1 pro-
tein is stabilized and translocated into the nucleus [19], 
where it binds to HREs to regulate expression of its target 
genes (Figure 2). In addition to VHL, murine double minute 
2 [30] and Jab1 [31] have also been reported to affect the 
ubiquitination and stability of HIF-1. It should be pointed 
out that the protein stability and transcriptional activity of 
HIF-1 can be regulated by several other factors besides hy-
poxia, such as the accumulation of intermediate metabolites, 
the loss of tumor-suppressor function and the gain of onco-
gene function [32].  
HIF-1 protein can be degraded by a mechanism that is 
independent of VHL, hypoxia and the ubiquitination ma-
chinery [33]. SHARP1, a crucial regulator of the invasive 
and metastatic phenotype in triple-negative breast cancer, 
was reported to inhibit the aggressiveness of the subtype of 
cancer through binding to HIF-1 and HIF-2. SHARP1 
acts as the HIF-presenting factor to the proteasome resulting 
in the proteasomal degradation of HIF-1 and HIF-2 
(Figure 2). Remarkably, histone deacetylase (HDAC) inhib-
itors have also been shown to induce the proteasomal deg-
radation of HIF-1 in a mechanism that is independent of 
VHL or the ubiquitin system. The mechanism involves the 
enhanced interaction of HIF-1 with heat shock protein 
(HSP) 70 and is secondary to a disruption of the 
HSP70/HSP90 axis function that appears to be mediated by 
the activity of HDAC-6 [34]. 
2  Sumoylation and HIF-1 
The small ubiquitin-related modifiers (SUMOs) share only 
about 18% sequence identity with ubiquitin, but SUMOs 
and ubiquitin are structurally quite similar. Four SUMO 
paralogues (designated SUMO-1, -2, -3, and -4) have been 
identified in mammals [35]. Like ubiquitin, SUMOs can be 
covalently attached to lysine residues within their target 
proteins via an enzymatic cascade involving a heterodimeric 
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Figure 2  Regulation of the stability and transcriptional activity of HIF-1 protein by sumoylation. 
E1-activating enzyme (SAE1/2), an E2-conjugating enzyme 
(Ubc9), and a growing number of distinct E3 ligases (Figure 
3), which can increase the efficiency and specificity of the 
sumoylation process [36]. The activated SUMOs are trans-
ferred from the heterodimeric E1 to Ubc9 through a thioe-
ster linkage between diglycine residues at the extreme C 
terminus of mature SUMO proteins and the active site cys-
teine of Ubc9. Subsequently, the SUMO moiety is ligated 
onto an acceptor lysine residue of a substrate in a process 
that can be enhanced by a SUMO E3 ligase. However, Ubc9 
is sufficient to promote substrate sumoylation, in the ab-
sence of ligase, at least in vitro [36,37]. 
Sumoylation has emerged as an important regulatory 
posttranslational event in mammals, as evidenced by the 
embryonic lethality of mouse mutants lacking Ubc9 [38]. 
Sumoylation modulates a diverse range of biological pro-
cesses such as gene transcription, DNA replication and re-
pair, chromosome segregation, and the transport of proteins 
through the nuclear pore [36,39,40]. In addition to the co-
valent attachment of SUMOs to lysine residues in target 
proteins, some specific motifs mediate non-covalent inter-
actions with SUMOs [4144]. In general, these motifs 
comprised a hydrophobic core, which is often flanked by 
acidic residues. The best-characterized SUMO interaction 
motifs (SIMs) have the consensus sequence, V/I-X-V/I-V/I 
or V/I-V/I-X-V/I/L, where X is any amino acid [43,44]. 
Structural studies have demonstrated that these hydrophobic 
SIMs bind to the second -strand and the first  helix of 
SUMOs. With increased attention focused on the non-  
covalent interaction of SUMOs with SIM-containing pro-
teins, it has become clear that there is some flexibility in 
 
Figure 3  The sequential activation of an enzymatic cascade for protein 
sumoylation from SUMO maturation by SENPs, SUMO activation by the 
E1 enzyme, conjugation to the E2 enzyme UBC9, SUMO linkage to the 
protein substrate by E3 ligase and SUMO deconjugation. 
the precise sequence of the hydrophobic core of the SIMs. 
For example, the corepressor CoREST1 binds to SUMO-2 
via a SIM with a five amino acid core in which positions 1, 
3 and 5 are hydrophobic residues [45]. Such results suggest 
that further variation in consensus SIMs will be found, em-
phasizing the importance of testing the functionality of po-
tential SIMs. 
Previous studies of HIF-1 sumoylation have produced 
conflicting results [4649]. Originally, Bae et al. [46] found 
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that ectopic SUMO-1 expression in HEK 293T cells in-
creases the stability of cotransfected HIF-1, thus enhanc-
ing the transcriptional activity of HIF-1 protein in which 
HIF-1 is sumoylated at lysines 391 and 477. Carbia-  
Nagashima et al. [48] reported that the RWD-containing 
sumoylation enhancer (RSUME) is induced by hypoxia and 
enhances overall SUMO-1, -2, and -3 conjugation. Moreo-
ver, RSUME enhances HIF-1 sumoylation, thus promot-
ing the stabilization and transcriptional activities of HIF-1 
during hypoxia.  
Berta et al. [47] revealed that HIF-1 undergoes sumoy-
lation by SUMO-1, -2 and -3 in vitro, in proximity to, and 
within the ODDD domain, in a process promoted by the 
SUMO E3 ligase RanBP2/Nup538. However, contrary to 
the studies mentioned above, they found that in vivo 
sumoylation does not change HIF-1 turnover rate and de-
creases its transcriptional activity. The SUMO E3 ligase 
PIASy was also reported to enhance hypoxia-induced 
HIF-1 sumoylation and to negatively regulate its stability 
and transactivation [50]. Furthermore, sentrin/SUMO-  
specific protease 1 (SENP1), a desumoylation enzyme, sta- 
bilizes HIF-1 and enhances its transcriptional activity by 
removing SUMO. This was proposed to be because sumoy-
lation of HIF-1 promotes its binding to VHL through a 
proline hydroxylation-independent mechanism, leading to 
HIF-1 ubiquitination and degradation (Figure 2) [49].  
3  Cbx4 and HIF-1 sumoylation 
Polycomb group (PcG) proteins are major transcriptional 
repressors that epigenetically modify chromatin. PcGs in-
clude structurally diverse and functionally related proteins, 
many of which interact with each other to form multimeric, 
chromatin-associated protein complexes called polycomb 
repressive complexes (PRC), e.g., PRC1 and PRC2 in 
mammals. These complexes are important for the regulation 
of many biological processes such as the cell-division cycle, 
DNA repair, cell differentiation, senescence and death. Cbx 
proteins, including Cbx2, Cbx4, Cbx6, Cbx7, and Cbx8, are 
the core components of the PRC1 complex. The classifica-
tion of members of the Cbx family is based on the presence 
of a single N-terminal chromodomain (Figure 1A), which, 
in at least some members of the family, can bind to histone 
proteins via methylated lysine residues [51]. More interest-
ingly, human Cbx4 (also known as polycomb 2, Pc2) also 
has SUMO E3 ligase activity [51], for which a limited rep-
ertoire of substrates have been identified, including 
C-terminus binding protein 1 [52], DNA methyltransferase 
3a [53], Smad-interacting Protein 1 [54], centrin-2 [55], and 
homeodomain-interacting protein kinase 2 [56]. 
Recently, we reported that Cbx4 directly interacts with, 
and enhances overall SUMO-1, -2, and -3 conjugation to 
HIF-1 protein in HCC cells. HIF-1 can be desumoylated 
by ectopic SENP1 expression. Under hypoxic conditions, 
the silencing of Cbx4 by its specific shRNAs inhibits 
HIF-1 sumoylation in HCC cells [17]. Recent analyses 
have shown that for Cbx4 two functional SIMs (SIM1 and 
SIM2, Figure 1A) are prerequisites for its SUMO E3 ligase 
activity [57,58]. For HIF-1 sumoylation, SIM1 of Cbx4 
contributes to its interaction with HIF-1 protein, and SIM2 
is essential for its SUMO E3 ligase activity. Furthermore, 
we found that Cbx4 promotes HIF-1 sumoylation at ly-
sines 391 and 477 within the ODDD of HIF-1. Intriguing-
ly, HIF-1 with mutations of these two sumoylation sites 
still interacts with Cbx4 with similar binding affinity to that 
of wild-type HIF-1, and it can also be recruited to the 
promoter region of HIF-1 targeted gene vascular endothelial 
growth factor (VEGF) together with Cbx4. However, the 
DNA binding ability and transcriptional activity of mutated 
HIF-1 cannot be enhanced by Cbx4. Therefore, we con-
clude that Cbx4 upregulates the transcriptional activity of 
HIF-1 through enhancing the sumoylation of HIF-1 at 
K391 and K477, as depicted in Figure 2 [17].  
4  HIF-1 sumoylation and cancer 
As described above, HIF-1 has been established as a 
strong promoter of tumor progression by effects on pro-
cesses including neovascularization, glucose metabolism, 
energy metabolism, migration, invasion, autophagy and cell 
death [59]. As sumoylation might regulate the stability 
and/or transcriptional activity of HIF-1, the regulators of 
HIF-1 sumoylation are presumed to play crucial roles in 
tumorigenesis. Indeed, PIASy was reported to inhibit the 
angiogenic activity of endothelial cells, and its expression is 
inversely correlated with tumor angiogenesis in colon can-
cer [50]. SENP1 is highly expressed in both precancerous 
prostate intraepithelial neoplasia lesions and prostate cancer 
tissues, and its expression correlates with prostate cancer 
aggressiveness and recurrence [60,61]. With in vitro and in 
vivo assays, SENP1 is recognized as a promoter of colony 
formation, migration, invasion, tumor growth and metasta-
sis in nude mice of prostate cancer cell lines [61]. In addi-
tion, SENP1 inhibition promotes the apoptosis of Burkitt 
lymphoma cells [62].  
It has been reported that SUMO-1 is highly expressed in 
HCC cell lines and clinical HCC samples, while the expres-
sion level of SUMO-1 in non-neoplastic liver tissues was 
significantly lower [63]. Analysis of a large cohort of HCC 
tissues allowed us to report that Cbx4 is highly expressed in 
most of these tissues, and that elevated Cbx4 protein is pos-
itively correlated with poor overall survival of HCC patients 
[54]. Wang et al. [64] also showed that Cbx4 expression 
was upregulated in multiple HCC cell lines and clinical  
samples, and that HCC patients with a high level of cyto-
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plasmic Cbx4 have a shorter overall and recurrence-free 
survival. Intriguingly, our further investigations demon-
strated that Cbx4 expression is also positively correlated 
with VEGF expression and microvessel density (MVD) [17]. 
In line with these clinical observations, overexpression of 
Cbx4 but not other members of the Cbx family promotes 
VEGF expression and in vitro angiogenesis in several HCC 
cell lines under hypoxia. Conversely, silencing of Cbx4 by 
shRNAs dramatically blocks hypoxia-induced VEGF pro-
duction and in vitro angiogenesis. The Cbx4-CDM mutant 
(F11A/W35L double-mutation in the chromodomain of 
Cbx4) has lost its polycomb function but still possesses 
SUMO E3 ligase activity. Ectopic expression of the 
Cbx4-CDM mutant increases hypoxia-induced VEGF pro-
duction and the hypoxia-induced tube-forming ability of 
vascular endothelial cells to a similar degree to wild-type 
Cbx4. In contrast, no such increases are seen for all three 
Cbx4-SIM mutants, which maintain the polycomb func-
tion but lose SUMO E3 ligase activity [17]. Conversely, the 
knockdown of HIF-1 or HIF-1 with their specific 
shRNAs almost completely abolishes hypoxia-induced 
VEGF expression, supporting the essential role of HIF-1 
sumoylation in Cbx4-dependent VEGF expression.  
In line with these in vitro findings, subcutaneously and 
orthotopically transplanted tumors originated from HCC 
cell lines ectopically expressing wild-type Cbx4 or its CDM 
mutant, but not the Cbx4-SIM1/2 mutant, grew much fast-
er compared with vehicle controls. Accordingly, ectopic 
expression of Cbx4 or Cbx4-CDM, but not Cbx4-SIM1/2, 
dramatically increases VEGF expression and MVD in the 
transplanted tumors [17]. Moreover, orthotopically trans-
planted SMMC-7721 [17] and MHCC97L cells [65] ectop-
ically expressing Cbx4 and Cbx4-CDM present significant-
ly more lung metastasis nodules than vehicle and Cbx4- 
SIM1/2-infected tumors. Conversely, the knockdown of 
endogenous Cbx4 causes SMMC-7721 and MHCC97L cells 
to produce significantly lower tumor burden than cells 
transfected with vehicle alone in BALB/c nude mice [17]. 
5  Perspectives 
The physiological and pathophysiological roles of HIF-1 
have been widely recognized and its post-translational mod-
ifications have attracted wide interest. However, HIF-1 
sumoylation appears to be very complicated. Dimova and 
Kietzmann [15] proposed that the effects of sumoylation on 
HIF-1 vary from cell type to cell type. More intriguingly, 
we have shown that Cbx4 and PIASy-mediated HIF-1 
sumoylations have different effects on the stability and 
transcriptional activity of HIF-1 in HCC cell lines. Actually, 
PIASy has no effect on both K391 and K477-mutated 
HIF-1, suggesting that Cbx4 and PIASy promote HIF-1 
sumoylations at different lysines. Therefore, we propose 
that different sumoylation patterns produced by specific 
SUMO E3 ligases might lead to different influences on the 
stability and transcriptional activity of HIF-1. However, 
the sumoylation sites of HIF-1 by PIASy and other SUMO 
E3 ligases remain to be identified. Alternatively, different 
sumoylation patterns produced by different SUMO E3 lig-
ases could possibly affect HIF-1-interacting proteins, 
which could contribute to the regulation of the stability and 
transcriptional activity of HIF-1 indirectly. Therefore, it 
remains to be further explored how Cbx4-induced HIF-1 
sumoylation at K391 and K477 increases the DNA binding 
ability and thus the transcriptional activity of HIF-1.  
It has previously been shown that some coactivators and 
corepressors contribute to the regulation of the transcrip-
tional activity of HIF-1 [66–68]. We presume that sumoy-
lation could affect the interaction of HIF-1 with these 
known or unknown co-modulators, thus regulating its tran-
scriptional activity. In fact, our preliminary proteomic ex-
periments do indeed reveal different interaction partners for 
non-sumoylated HIF-1 and HIF-1 proteins with Cbx4- 
enhanced sumoylation. Therefore, it would be useful to ex-
plore these interaction partners and their roles in the regula-
tion of stability and function of HIF-1 to uncover the 
mechanism by which sumoylation of HIF-1 regulates its 
transcriptional activity. Regardless of the outcome of such 
investigations, the development of reagents targeting the 
SUMO E3 ligase activity of Cbx4, and the interacting sites 
between Cbx4 and HIF-1, could be beneficial for inhibit-
ing the tumor angiogenesis essential for cancer cells to ful-
fill their need for oxygen and nutrients. 
Finally, increasing lines of evidence have shown that 
hypoxia and HIF-1 contribute to differentiation of acute 
myeloid leukemia [69–75], consistent with the fact that 
people living at high altitude appear to have a lower risk of 
leukemia [76–79]. Our investigations showed that 
HIF-1-mediated leukemic cell differentiation is independent 
of the transcriptional activity of HIF-1 [80]. In short, hy-
poxia-stabilized HIF-1 interacts with and increases the 
transcriptional activity of C/EBP and Runt-related protein 
1 (Runx1, also named acute myeloid leukemia-1, AML1) 
[81–83]. Therefore, the question of whether sumoylation of 
HIF-1 contributes to leukemogenesis and leukemic cell 
differentiation deserves further investigation. 
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